ImportRefusal LogoImportRefusal

Shree Marwal Sevashram

⚠️ High Risk

FEI: 3008855266 • Indore, Madhya Pradesh • INDIA

FEI

FEI Number

3008855266

📍

Location

Indore, Madhya Pradesh

🇮🇳

Country

INDIA
🏢

Address

4 - 5 A B Industrial Est, Plot No; Baolia Khurd, Indore, Madhya Pradesh, India

High Risk

FDA Import Risk Assessment

51.9
LowModerateHighCritical

This firm has a significant history of FDA import refusals with notable violations.

Statistics

15
Total Refusals
2
Unique Violations
10/9/2013
Latest Refusal
6/27/2011
Earliest Refusal

Score Breakdown

Violation Severity
80.0×40%
Refusal Volume
44.6×30%
Recency
0.0×20%
Frequency
65.6×10%
How is this score calculated?

Proprietary Algorithm

  • 40% Violation Severity — AI-assessed (1-10)
  • 30% Refusal Volume — Logarithmic scale
  • 20% Recency — Decays over 5 years
  • 10% Frequency — Refusals per year

© ImportRefusal.com Original Analysis

Violation Summary

7515×

UNAPPROVED

The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).

1185×

NOT LISTED

It appears the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by section 510(j) or 510(k).

Refusal History

DateProductViolationsDivision
10/9/2013
66VBL99MISCELLANEOUS PATENT MEDICINES, ETC.
75UNAPPROVED
Seattle District Office (SEA-DO)
9/14/2012
66VBK99MISCELLANEOUS PATENT MEDICINES, ETC.
118NOT LISTED
75UNAPPROVED
New Orleans District Office (NOL-DO)
9/7/2012
60LCL99ANALGESIC, N.E.C.
118NOT LISTED
75UNAPPROVED
New Orleans District Office (NOL-DO)
8/15/2012
66VCL99MISCELLANEOUS PATENT MEDICINES, ETC.
118NOT LISTED
75UNAPPROVED
New Orleans District Office (NOL-DO)
8/14/2012
66VBO99MISCELLANEOUS PATENT MEDICINES, ETC.
75UNAPPROVED
New Orleans District Office (NOL-DO)
8/14/2012
60LAL99ANALGESIC, N.E.C.
75UNAPPROVED
New Orleans District Office (NOL-DO)
8/9/2012
66VAY99MISCELLANEOUS PATENT MEDICINES, ETC.
118NOT LISTED
75UNAPPROVED
New Orleans District Office (NOL-DO)
8/9/2012
62GBX99ANTI-INFLAMMATORY N.E.C.
75UNAPPROVED
New Orleans District Office (NOL-DO)
8/7/2012
62GBK99ANTI-INFLAMMATORY N.E.C.
75UNAPPROVED
New Orleans District Office (NOL-DO)
8/2/2012
66VCP99MISCELLANEOUS PATENT MEDICINES, ETC.
75UNAPPROVED
New Orleans District Office (NOL-DO)
7/27/2012
66VBL99MISCELLANEOUS PATENT MEDICINES, ETC.
75UNAPPROVED
New Orleans District Office (NOL-DO)
7/6/2012
53LD99OTHER SKIN CARE PREPARATIONS, N.E.C.
75UNAPPROVED
New Orleans District Office (NOL-DO)
7/6/2012
53LD99OTHER SKIN CARE PREPARATIONS, N.E.C.
75UNAPPROVED
New Orleans District Office (NOL-DO)
4/20/2012
60LBL99ANALGESIC, N.E.C.
75UNAPPROVED
New Orleans District Office (NOL-DO)
6/27/2011
62GBY99ANTI-INFLAMMATORY N.E.C.
118NOT LISTED
75UNAPPROVED
Seattle District Office (SEA-DO)

Frequently Asked Questions

What is Shree Marwal Sevashram's FDA import refusal history?

Shree Marwal Sevashram (FEI: 3008855266) has 15 FDA import refusal record(s) in our database, spanning from 6/27/2011 to 10/9/2013.

What is an FEI number?

FEI stands for Firm Establishment Identifier. It's a unique number assigned by the FDA to identify establishments that manufacture, process, pack, or hold food, drugs, medical devices, or other FDA-regulated products. Shree Marwal Sevashram's FEI number is 3008855266.

What types of violations has Shree Marwal Sevashram received?

Shree Marwal Sevashram has been cited for 2 different violation type(s). Common FDA violations include adulteration (unsafe or unsanitary products), misbranding (incorrect or misleading labels), and regulatory non-compliance.

Where does this information about Shree Marwal Sevashram come from?

All FDA import refusal data for Shree Marwal Sevashram is sourced from the official FDA Data Dashboard (datadashboard.fda.gov), a public government database maintained by the U.S. Food and Drug Administration.

Data sourced from the FDA Data Dashboard, a public database maintained by the U.S. Food and Drug Administration.